Kymera Therapeutics, Inc. Common Stock (KYMR) Financials
Key financial figures for Kymera Therapeutics, Inc. Common Stock (Q3 2026).
Kymera reports a Q3 2026 GAAP loss of $1.32 per share on no collaboration revenue and positive KT-579 Phase 1 data; $1.65B cash, runway into 2029. GAAP EPS of -$1.32 vs -$0.94 a year earlier; vs FMP estimate of -$1.26, a miss of $0.06. No collaboration revenue (vs $2.8M a year earlier); the company does not expect additional collaboration revenue in 2026. R&D expense $128.5M vs $74.1M, driven by the STAT6 program, platform and discovery programs, and R&D headcount growth; net loss $132.0M vs $82.2M. $1.65B in cash, cash equivalents and marketable securities at September 30, 2026, with runway guided into 2029. Figures are for Q3 2026, as Kymera Therapeutics Inc. reported them.
- Revenue
- $0
- Net Income
- -$132M
- EPS
- $-1.32
- Total Assets
- $1.8B
- Operating Cash Flow
- -$78M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$132M | -$1.32 | -$78M | |
| Q2 FY2026 | $65M | -$61M | -$0.62 | -116.32% | -$55M |
| Q1 FY2026 | $34M | -$69M | -$0.71 | -244.88% | -$89M |
| Q4 FY2025 | $3M | -$87M | -$0.98 | -3422.94% | -$67M |
| Q3 FY2025 | $3M | -$82M | -$0.94 | -3347.36% | -$27M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $39M | -$311M | -$3.69 | -891.33% | -$234M |
| FY2024 | $47M | -$224M | -$2.98 | -555.82% | -$207M |
| FY2023 | $79M | -$147M | -$2.52 | -210.62% | -$137M |
Frequently asked questions
What was Kymera Therapeutics Inc.'s revenue last quarter?
Kymera Therapeutics Inc. reported revenue of $0.00 for Q3 FY2026, down 100.0% from the same period a year earlier.
Is Kymera Therapeutics Inc. profitable?
Not in its most recent reported period. Kymera Therapeutics Inc. reported a net loss of $132.0 million for Q3 FY2026.
How much free cash flow did Kymera Therapeutics Inc. generate?
Kymera Therapeutics Inc. generated free cash flow of -$78.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Kymera Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.